Most recently, Mr. Brindle served as President of Novartis Group China, where he oversaw five business entities and led a team of approximately 8,500 employees. In this role, he was responsible for formulating and executing the company’s integrated strategy in one of its most strategically important global markets. His leadership focused on strengthening policy dialogue, enhancing market access, and building strategic partnerships across government, academia, and industry to support the delivery of innovative, value-based healthcare solutions.

Prior to Novartis, Mr. Brindle held senior executive roles in public affairs, policy, and business development at Eli Lilly, Pfizer, and GSK, where he led external engagement efforts across Asia-Pacific and emerging markets. His work included high-level policy initiatives, intellectual property strategy, pricing and reimbursement negotiations, and the establishment of public-private partnerships with health authorities and regulatory agencies.

In addition to his corporate leadership, Mr. Brindle served as CEO of Cheerland Biotechnology, a China-based biotechnology company, and was a partner at ZY Partners, a prominent Chinese law firm focused on corporate and intellectual property law. Earlier in his career, he served as Legislative Counsel for a U.S. Senator, advising on international affairs.

Mr. Brindle has been actively involved in shaping regional and global health policy through contributions to initiatives such as the APEC Life Sciences Innovation Forum, the Thai Center for Excellence in Life Sciences (TCELS), and the US-ASEAN Business Council. His career is distinguished by a consistent ability to navigate complex geopolitical environments and foster alignment among diverse stakeholders.